# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0191 |
| PP ID | PP-0191 |
| Title | Biomarker Testing for Targeted Therapy |
| Version | 1.0.0 |
| QA Status | PASS — GOLD |
| Decision Status | Approved / Locked |
| Gold Standard | FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1 |
| Governance Standard | CORE_WORKING_RULES v1.7 |

---

# 1. QA Objective

This QA Report verifies that the PP-0191 Gold package:

1. follows the approved and locked Decision Batch;
2. follows the Gold Population Package Specification;
3. preserves the absolute Gold depth standard;
4. remains patient-facing and educational;
5. remains source-grounded in the project Source Materials;
6. does not duplicate substantive ownership of adjacent Population Packages;
7. maintains the required Knowledge Graph;
8. preserves evidence traceability;
9. avoids unsafe individualized treatment recommendations;
10. contains the complete four-artifact package structure.

---

# 2. Artifact Completeness

| Required Artifact | Present | Status |
|---|---:|---|
| `01_CKO.md` | Yes | PASS |
| `02_KNOWLEDGE_PASSPORT.md` | Yes | PASS |
| `03_PRIMARY_EVIDENCE_PACKAGE.md` | Yes | PASS |
| `04_QA_REPORT.md` | Yes | PASS |

**Artifact completeness: PASS**

---

# 3. Gold Structure QA

## 3.1 Clinical Knowledge Object

Required Gold elements verified:

- Identity metadata.
- Educational objectives.
- Included scope.
- Not-included scope.
- Independent clinical knowledge blocks.
- Patient-facing explanations.
- Common misconceptions.
- Key messages.
- Knowledge Graph.
- Clinical safety boundary.
- Revision history.

**Result: PASS**

---

## 3.2 Knowledge Passport

Required Gold elements verified:

- Identity.
- Classification.
- Clinical-educational role.
- Clinical scope.
- Boundary ownership map.
- Retrieval intent.
- Retrieval tags.
- Evidence classification.
- Source hierarchy.
- Evidence traceability.
- Patient-facing retrieval safety.
- Knowledge Graph.
- Intended runtime behavior.
- Governance metadata.
- Registry identity note.
- Version control.
- Final status.

**Result: PASS**

---

## 3.3 Primary Evidence Package

Required Gold elements verified:

- Clinical question.
- Educational intent.
- Included scope.
- Excluded scope.
- Primary sources.
- Supporting sources.
- Evidence hierarchy.
- Evidence matrix.
- Evidence discussion.
- Clinical testing model.
- Testing strategy matrix.
- Evidence consistency review.
- Evidence gaps.
- Out-of-scope delegation map.
- Future update triggers.
- Source traceability.
- Source-first note.
- Evidence package decision.
- Final evidence status.

**Result: PASS**

---

## 3.4 QA Report

Required four QA layers verified:

- Content QA.
- Clinical QA.
- Educational QA.
- Governance QA.

Additional boundary, overlap, evidence-traceability, safety, and Gold-depth checks are included.

**Result: PASS**

---

# 4. Content QA

## 4.1 Atomic Knowledge Principle

The package answers one educational question:

> **Which biomarker testing should be considered to identify potential targeted-treatment opportunities in gastric adenocarcinoma?**

The package does not attempt to become:

- a general targeted-therapy package;
- a treatment-selection package;
- an individual biomarker-methodology package;
- an NGS technology package;
- a molecular-report literacy package.

**PASS**

---

## 4.2 Scope Completeness

The locked scope is represented across:

- CKO;
- Knowledge Passport;
- Evidence Package;
- QA boundary.

Core topics are not limited to a superficial definition of testing.

The package includes:

- testing purpose;
- predictive biomarker concept;
- clinical question;
- targeted versus broad testing;
- HER2;
- CLDN18.2;
- selected molecular targets;
- NGS;
- specimen considerations;
- tissue versus blood;
- negative/inadequate results;
- testing completeness;
- additional-testing concept;
- patient questions;
- downstream boundaries.

**PASS**

---

## 4.3 No Unapproved Scope Expansion

The package does not introduce:

- universal NGS requirements;
- universal testing of every rare biomarker;
- universal repeat-testing schedules;
- individualized treatment recommendations;
- drug dosing;
- treatment toxicity management;
- response/resistance algorithms.

**PASS**

---

# 5. Clinical QA

## 5.1 Evidence Hierarchy

Disease-specific guidance is led by NCCN v2.2026.

Cross-cutting genomic-testing concepts are supported by ESMO-ASCO.

NCI and ACS are used for patient-facing clinical context.

**PASS**

---

## 5.2 NCCN Consistency

The package preserves the following NCCN concepts:

- HER2 testing in the appropriate advanced/metastatic context.
- CLDN18.2 testing in the appropriate advanced/metastatic context.
- IHC/ISH/targeted PCR as preferred initial approaches for specified biomarkers.
- Selected use of validated NGS.
- Requirement for sufficient tumor tissue for selected NGS use.
- NGS as a method capable of assessing multiple molecular events.
- ctDNA as a blood-based liquid-biopsy approach.
- Selected use of blood-based genomic testing when tissue is limited or traditional biopsy is not feasible.

**PASS**

---

## 5.3 No Universal-NGS Claim

The package explicitly states that NGS is not automatically required for every patient and does not universally replace biomarker-specific assays.

**PASS**

---

## 5.4 No Universal-Testing Claim

The package does not claim that every patient must undergo every possible targeted biomarker test.

Testing is framed as clinical-question-driven.

**PASS**

---

## 5.5 No Automatic Treatment Claim

The package explicitly separates:

**biomarker detected**

from

**clinically actionable**

from

**treatment selection**

from

**treatment administration**.

**PASS**

---

## 5.6 Negative Result Safety

The package does not equate:

> "negative"

with:

> "no molecular alteration exists."

It explicitly ties a negative result to test scope and limitations.

**PASS**

---

## 5.7 Failed / Inadequate Testing

The package explicitly distinguishes:

- negative/not detected;
- inadequate/failed/insufficient.

This prevents a technically unsuccessful test from being interpreted as a true negative.

**PASS**

---

## 5.8 Tissue / Blood Safety

The package does not claim that blood-based genomic testing universally replaces tissue.

It uses the Source Materials' selected-context framing.

**PASS**

---

## 5.9 Germline Safety

The package does not equate tumor findings with inherited findings.

Possible germline implications are explicitly separated from somatic/tumor testing.

**PASS**

---

# 6. Educational QA

## 6.1 Patient-Friendly Language

Medical terms are introduced with explanations where needed.

The package uses:

- short conceptual paragraphs;
- explicit distinctions;
- patient-facing questions;
- misconception/correction format;
- stepwise testing models.

**PASS**

---

## 6.2 Logical Flow

The package follows the clinical reasoning sequence:

**Why test?**

↓

**What question are we asking?**

↓

**Which biomarker information matters?**

↓

**Which testing strategy may answer the question?**

↓

**What specimen is available?**

↓

**What does the result mean at a high level?**

↓

**What happens next?**

This preserves the intended testing-strategy role.

**PASS**

---

## 6.3 Terminology

The package distinguishes:

- biomarker;
- predictive biomarker;
- testing strategy;
- targeted assay;
- molecular profiling;
- NGS;
- specimen;
- negative;
- inadequate/failed;
- actionable;
- treatment selection.

**PASS**

---

# 7. Governance QA

## 7.1 Source-First Rule

The production scope was derived from project Source Files including:

- governance documents;
- approved Discussion example;
- PP Registry;
- adjacent Gold artifacts;
- gastric-cancer NCCN;
- ESMO-ASCO;
- NCI;
- ACS.

**PASS**

---

## 7.2 User-Controlled Sequence

The package was generated only because the Project Coordinator explicitly approved and locked PP-0191.

No automatic progression to another PP was performed.

**PASS**

---

## 7.3 Immediate Artifact Production

The package was generated immediately after the PP-0191 Decision Batch was approved and locked.

No additional confirmation about:

- format;
- depth;
- structure;
- ZIP packaging

was required.

**PASS**

---

## 7.4 Gold Depth

The package preserves the required Gold depth across:

- CKO;
- Knowledge Passport;
- Primary Evidence Package;
- QA.

The artifacts are not intentionally compacted, summarized, or structurally abbreviated relative to the approved Gold reference standard.

**PASS**

---

# 8. Adjacent Population Package Overlap QA

## PP-0181 — HER2 Testing

### PP-0181 owns

Detailed HER2 testing:

- purpose;
- specimen;
- IHC;
- ISH/FISH;
- interpretation;
- HER2-specific testing considerations.

### PP-0191 owns

Why HER2 testing may be relevant as part of targeted-treatment testing strategy.

**No substantive duplication identified.**

**PASS**

---

## PP-0184 — CLDN18.2 Testing

### PP-0184 owns

Detailed CLDN18.2 testing/scoring.

### PP-0191 owns

Why CLDN18.2 testing may be relevant before targeted-treatment consideration.

**No substantive duplication identified.**

**PASS**

---

## PP-0187 — NGS Biomarker Testing

### PP-0187 owns

NGS testing itself.

### PP-0191 owns

When broader molecular profiling may be relevant as a testing-strategy choice.

**No substantive duplication identified.**

**PASS**

---

## PP-0189 — Molecular Report Literacy

### PP-0189 owns

How to understand a molecular/genomic report.

### PP-0191 owns

What testing strategy should be considered before the report exists.

**Clean boundary preserved.**

**PASS**

---

## PP-0190 — Biomarker-Directed Treatment Selection

### PP-0190 owns

How a biomarker result directs targeted-treatment selection.

### PP-0191 owns

How to determine what biomarker information/testing may be needed before that downstream decision.

**Critical boundary preserved.**

**PASS**

---

## PP-0208+ — Targeted Treatment

### Downstream treatment PPs own

Drug, regimen, treatment application, toxicity, response and related management.

### PP-0191 owns

Testing strategy only.

**No treatment-package duplication identified.**

**PASS**

---

# 9. Knowledge Graph QA

## Prerequisite

- Foundational biomarker-testing concepts.
- Relevant individual biomarker-testing packages.
- NGS biomarker testing.

## Related

- PP-0181–PP-0188.
- PP-0189.
- Somatic genetic testing.
- Liquid biopsy/ctDNA.
- Companion diagnostics.
- Hereditary/genetic-testing packages.

## Downstream

**PP-0190 — Biomarker-Directed Treatment Selection**

↓

**PP-0208 — Targeted Therapy in Gastric Cancer**

↓

therapy-specific packages.

**Knowledge Graph connectivity: PASS**

---

# 10. Evidence Traceability QA

Major claims are traceable to the project Source Materials:

### NCCN Gastric Cancer v2.2026

Supports:

- biomarker testing context;
- HER2;
- CLDN18.2;
- IHC/ISH/targeted PCR;
- NGS;
- molecular events;
- ctDNA/liquid biopsy;
- selected blood-based genomic testing.

### ESMO-ASCO 2023

Supports:

- molecular assay spectrum;
- analyte/panel/broader genomic testing;
- molecular alteration classes;
- specimen/pre-analytic variables;
- clinical-context interpretation;
- germline implications.

### NCI Treatment of Stomach Cancer

Supports:

- biomarker testing in relation to targeted therapy.

### ACS Stomach Cancer

Supports:

- HER2;
- CLDN18.2;
- NTRK;
- BRAF;
- RET patient-facing treatment/testing examples.

### NCI Genetics PDQ

Supports:

- VUS;
- multigene testing;
- possible germline findings;
- counselling/follow-up concepts.

**Evidence traceability: PASS**

---

# 11. Evidence Gap QA

The package explicitly identifies rather than silently fills:

- lack of a universal testing sequence;
- assay-specific variation;
- lack of universal sensitivity thresholds;
- context-dependent NGS use;
- tissue-versus-blood limitations;
- absence of universal repeat-testing schedules;
- need for individualized clinical context.

**PASS**

---

# 12. Patient-Safety QA

The package contains no instruction to an individual patient to:

- start treatment;
- stop treatment;
- change treatment;
- obtain a specific test without clinician review;
- interpret an individual result as definitive treatment eligibility.

It repeatedly redirects individualized decisions to the cancer care team.

**PASS**

---

# 13. Boundary QA

The locked ownership boundary is:

### Core

Targeted-treatment biomarker testing strategy: purpose, clinical-question-driven testing, targeted versus broader testing, HER2 and CLDN18.2 as representative domains, selected molecular targets, NGS strategy, specimen considerations, tissue-versus-blood context, negative/inadequate testing concepts, and patient-facing testing questions.

### Supporting

Predictive biomarker concept, companion-diagnostic concept, molecular multidisciplinary review, selected NTRK/BRAF V600E/RET/FGFR2 examples, clinical-trial relevance, and possible germline implications.

### Explicitly Excluded

Detailed individual biomarker testing/scoring, NGS methodology, sequencing/bioinformatics, variant interpretation/classification, molecular-report literacy, detailed ctDNA biology/monitoring, treatment selection, drug/regimen selection, treatment sequencing, toxicity/response/resistance management, individualized testing, and individualized treatment recommendations.

### Delegated-to PP

PP-0181, PP-0182, PP-0183, PP-0184, PP-0185, PP-0186, PP-0187, PP-0189, PP-0190, PP-0208, PP-0209, PP-0210, PP-0211, relevant liquid-biopsy/ctDNA packages, companion-diagnostics packages, hereditary/genetic-testing packages, and downstream therapy-specific packages.

**Boundary QA: PASS**

---

# 14. Registry Identity QA

The current project Source Files contain an older registry state in which PP-0191 appears under an immunotherapy-testing title.

The active Project Coordinator instruction and approved/locked Decision Batch explicitly define:

> **PP-0191 — Biomarker Testing for Targeted Therapy**

The artifact follows the explicit approved execution instruction.

The registry discrepancy is documented rather than silently rewritten.

**Impact on clinical artifact: non-blocking.**

**PASS**

---

# 15. Gold Depth QA

## Required principle

The project Gold rule establishes that future packages:

- may be deeper;
- must not be shorter;
- must not be compacted;
- must not reduce evidence detail;
- must not reduce QA detail;
- must not reduce Knowledge Graph detail;
- must not reduce patient-facing explanation.

The present package deliberately maintains:

- multiple clinical knowledge blocks;
- detailed scope ownership;
- evidence hierarchy;
- evidence matrix;
- clinical testing model;
- testing strategy matrix;
- consistency review;
- evidence gaps;
- delegation map;
- update triggers;
- four-layer QA;
- adjacent-package overlap review;
- Knowledge Graph treatment.

**Gold depth integrity: PASS**

---

# 16. Final QA Decision

## PASS

PP-0191 satisfies the locked Gold Population Package standard and the approved/locked PP-0191 Decision Batch.

The package maintains the intended architecture:

**Individual Biomarker / NGS Testing**

↓

**PP-0191 — Biomarker Testing for Targeted Therapy**

↓

**PP-0189 — Molecular Report Literacy**

↓

**PP-0190 — Biomarker-Directed Treatment Selection**

↓

**Targeted-Treatment Population Packages**

The package does not duplicate the substantive ownership of:

- individual biomarker testing;
- NGS methodology;
- molecular-report literacy;
- treatment selection;
- targeted-treatment management.

The package also avoids the unsafe shortcuts:

1. **Testing performed → treatment automatically indicated.**
2. **Negative test → all molecular targets absent.**
3. **Tumor finding → inherited finding.**
4. **NGS → universally required.**
5. **Broader testing → automatically better.**
6. **Blood test → universal replacement for tissue.**

These safeguards are central to the locked educational boundary.

---

# 17. Artifact Production QA

| Check | Result |
|---|---|
| 4 required Markdown artifacts | PASS |
| Gold structure | PASS |
| Gold depth | PASS |
| Evidence traceability | PASS |
| Patient-facing style | PASS |
| Knowledge Graph | PASS |
| Boundary consistency | PASS |
| Adjacent PP overlap check | PASS |
| Clinical safety | PASS |
| Governance compliance | PASS |
| Versioning | PASS |
| ZIP packaging | PASS |

---

# 18. Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
